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Background: Family health history (FHH) is the single strongest predictor of disease risk and yet is significantly
underutilized in primary care. We developed a patient facing FHH collection tool, MeTree©, that uses risk
stratification to generate clinical decision support for breast cancer, colorectal cancer, ovarian cancer, hereditary
cancer syndromes, and thrombosis. Here we present data on the experience of patients and providers after
integration of MeTree© into 2 primary care practices.
Methods: This was a Type 2 hybrid controlled implementation-effectiveness study in 3 community-based primary
care clinics in Greensboro, NC. All non-adopted adult English speaking patients with upcoming routine
appointments were invited. Patients were recruited from December 2009 to the present and followed for one year.
Ease of integration of MeTree© into clinical practice at the two intervention clinics was evaluated through patient
surveys after their appointment and at 3 months post-visit, and physician surveys 3 months after tool integration.
Results: Total enrollment =1,184. Average time to complete MeTree© = 27 minutes. Patients found MeTree©: easy
to use (93%), easy to understand (97%), useful (98%), raised awareness of disease risk (85%), and changed how they
think about their health (86%). Of the 26% (N = 311) asking for assistance to complete the tool, age (65 sd 9.4 vs. 57
sd 11.8, p-value < 0.00) and large pedigree size (24.4 sd 9.81 vs. 22.2 sd 8.30, p-value < 0.00) were the only significant
factors; 77% of those requiring assistance were over the age of 60. Providers (N = 14) found MeTree©: improved
their practice (86%), improved their understanding of FHH (64%), made practice easier (79%), and worthy of
recommending to their peers (93%).
Conclusions: Our study shows that MeTree© has broad acceptance and support from both patients and providers
and can be implemented without disruption to workflow.
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Family health history (FHH) has long been acknowl-
edged as an important part of the medical examination
[1]. In the current age of genomics, the importance of
FHH is becoming ever more apparent. According to
Francis Collins, “Virtually every human illness has a her-
editary component” [2] and current professional guide-
lines for cardiovascular disease [3], diabetes [4], breast
cancer [5], and colorectal cancer [6] among others strongly
endorse FHH risk stratification to develop personalized
prevention strategies. Despite this, collection and use
of FHH for clinical decision making in primary care is
underutilized.
Many barriers exist to the accurate and complete col-
lection and application of FHH within the traditional
primary care model. Patients are frequently unprepared
to provide FHH, usually due to either lack of communi-
cation among family members or failure to appreciate its
importance [7,8]. At the same time, physicians find it
difficult to acquire and use FHH due to time constraints,
lack of standardization, and difficulty synthesizing into
actionable prevention strategies [9-12].
Self-collection tools have been shown to be as good or
better than the current practice of FHH collection by
medical providers [13,14]. These factors make a patient-
oriented FHH collection and risk stratification tool a
compelling approach for overcoming barriers and im-
proving patient care. In 2004 the Genomedical Connec-
tion, a consortium of Duke University, the University of
North Carolina at Greensboro, and Cone Health System,
developed the Genomic Medicine Model (GMM). The
central component of the GMM was the creation of
MeTree©, a computerized FHH collection and decision
support tool for integration into primary care clinics, a
practice environment uniquely suited for widespread
population impact [8]. This manuscript describes the ex-
periences of the providers and patients at intervention
clinics who used MeTree© as part of a Department of
Defense (DoD) (grant # W81XWH-05 1-0383) funded
hybrid implementation-effectiveness controlled study.
Methods
MeTree©
MeTree© is a patient-facing FHH computerized collec-
tion tool with embedded clinical decision support (CDS)
for patients and providers on actionable prevention
strategies and education support for collecting FHH. Pa-
tients collect their FHH, then enter it into MeTree©
along with other relevant personal history needed to run
the integrated risk calculators. MeTree© then risk-stratifies
patients for five diseases (breast, ovarian and colorectal
cancer, thrombosis, and hereditary cancer syndromes) and
recommends risk-guided prevention strategies endorsed
by evidence-based guidelines [15-24]. CDS is provided inthe form of a pedigree and tabular FHH along with indi-
vidualized reports- one for patients with general com-
ments about their disease risk and points to discuss with
their providers, and another for providers outlining person-
alized action-oriented evidenced-based prevention strat-
egies along with details of the FHH triggers and resources
for additional information. Details regarding MeTree©’s de-
velopment and validation, including the evidence-based
guidelines, risk calculators, programming and validity have
been published [25].
We performed a controlled hybrid type 2 implementation-
effectiveness clinical trial in three community-based primary
care practices in Cone Health System, Greensboro,
NC. Hybrid studies are an emerging research tool for
combining studies with effectiveness and implementa-
tion outcomes; primary outcomes in type 2 studies are
effectiveness and secondary outcomes address both ef-
fectiveness and implementation [26,27]. The details of
the study design are reported in a previously published
protocol paper [28]. The study was IRB approved by all
3 institutions and the DoD. Written and informed con-
sent was obtained from all participants in the study.
Setting, participants, and intervention
MeTree© was integrated into the work flow of two
community-based primary care clinics, while the 3rd
served as a concurrent control for comparison of con-
temporaneous screening and referral rates. Clinic prac-
tices were compensated with a small sum of money for
their participation. Integration included educating pa-
tients about the importance of FHH and how to collect
it, providing a FHH worksheet to facilitate collection,
completing MeTree© at a dedicated clinic kiosk prior to
their appointment, and generating CDS output. Patient
reports were given to patients immediately and provider
reports were integrated into the medical record for use
at the patient visit. It was left up to the patient and the
provider to choose whether to act, or not, on MeTree©’s
recommendations. A study coordinator was available for
assistance.
Invitation letters were mailed to 11,177 patients with
upcoming primary care well visits at the two interven-
tion practices between October 15th 2009 and April
14th 2012. Children, adoptees, and non-English speakers
were excluded. Patients were required to enter their FHH
at the kiosk in the clinic and since only one kiosk was
available at each clinic, only one person per hour time slot
could enroll. See study flow diagram (Figure 1); of the
5,971 patients that were contacted by phone about the
study, 4,277 (72%) agreed to participate. Of the 5,971
contacted, 1,694 (28%) declined to participate, 288 (5%)
were unable to come one hour prior to their PCP appoint-
ment to complete MeTree©, 2,805 (47%) could not be
scheduled due to only one clinic kiosk being available per
Figure 1 Study flow diagram. Previously published: Orlando LA,
et al. [28].
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MeTree©.Outcomes and follow-up
All intervention clinic patients completed a baseline sur-
vey derived from the Health Information National Trends
Survey [29] at the time of study enrollment. They were
surveyed on disease risk perceptions, lifestyle, and their
knowledge of health, cancer and genetics. An exit survey,
completed after their primary care appointment, assessed
their experience with MeTree© and their discussions with
their provider. At 3 months post- MeTree©, patients re-
took the baseline survey and answered questions about
MeTree©’s impact on their health perceptions, cancer
screening practices, and discussions with family members.
Physicians were interviewed prior to implementation
regarding perceived barriers to integration and sur-
veyed at 3 months post-integration regarding their ex-
perience with MeTree©. All surveys were paper-based
and self-administered. Data were entered into RedCap
by study personnel [30].Statistical analysis
Data was analyzed using R statistical software and all hy-
potheses tests were assessed at a significance level of p < 0.05
[31]. Since the intervention was allocated at the level of the
clinic, to assess for the presence of data clustering, we calcu-
lated the design effect. The result, 1, indicated the absence of
clustering and permitted the use of standard models withoutadjustment [32]. We used Pearson's chi-square test to
analyze the independence of relationships for two categorical
variables and ANOVA F-test for one categorical and
one numeric variable. Fisher's least significant differ-
ence test assessed differences in pairs of levels. Linear
regression models and t-tests analyzed the relationship
of two numeric variables. When appropriate, numer-
ical outcome variables were analyzed using multivari-
ate analysis with standard linear regression, and categorical
variables with logistic linear regression. Acceptability was
evaluated based on: age, gender, ethnicity, education level,
family size, and percent of family with cancer. Odds ratios
for continuous variables, when used, were presented in the
following units: age, per one year increase; family size, per
one person increase; percent of family with cancer, per one
percent increase. For multivariate analyses related to pa-
tients’ experience using MeTree©, a covariate regarding
whether patients talked with relatives prior to using
MeTree© was also included. There were variable amounts
of missing data. For any particular analysis individuals with
missing data were dropped from that analysis. For subjects
that were lost to follow-up, reminders to complete the sur-
veys were sent three times.
Results
Patient characteristics
Characteristics of the 1,184 enrolled patients compared
to the general clinic population are presented in Table 1.
They entered information on 27,406 relatives.
Patient user experience
The user experience is presented in the following areas:
ease of use, time, satisfaction, and preparedness (Table 2).
Ease of use
All but 56 patients reported MeTree© was easy to use
and they did not feel rushed. Assistance from the study
coordinator was requested by 311/1173 (26.3%) patients
of whom 77% were aged over 60. Using a logistic regres-
sion model those with larger pedigrees (OR = 1.05, CI
1.03-1.07) and older age (OR = 1.07 CI 1.06-1.09) were
more likely to request help.
Time
The average time to complete MeTree© was 27.1 minutes
(range 8–118, SD 12.2) with only 31/885 (3.5%) feeling
they did not have enough time to complete their pedigree.
On a linear regression model, patients took longer to
complete MeTree© when: they had talked to their relatives
(coefficient 2.44, CI 1.22-3.66, p-value < 0.00), had more
relatives (coefficient 0.6, CI 0.53-0.68, p-value < 0.00), or
had more cancer in their family (coefficient 0.18, CI 0.12-
0.24, p-value < 0.00). For example, for every increase in
family size by one person, subjects took an additional
Table 1 Baseline characteristics of patients enrolled to
date as compared to the general clinic population
Study patients # (%) Baseline clinic
population # (%)
Patients 1184 45000
Gender
Male 490 (41.4%) 56.1%
Female 694 (58.6%) 42.7%
Ethnicity
White 969 (81.8%) 75.2%
Black 159 (13.5%) 15.47%
Other 56 (4.7%) 9.4%
Age
Mean (SD) 58.8 (11.79) 59.3 (13.5)
<50 250 (21.11%) NA
50-65 575 (48.56%) NA
>65 359 (30.32%) NA
Education
HS or less 158 (13.3%) NA
Some college 245 (20.7%) NA
College Deg 461 (38.9%) NA
Any Grad 320 (27.0%) NA
Gail score (SD) 0.0184 (0.01) NA
No. of relatives (range) 22.89 (8–71) NA
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who received assistance from the coordinator took less
time to complete their pedigrees (coefficient −5.58, CI
(−4.16)-(−7.00), p-value < 0.00). There was no differ-
ence in completion time by age, ethnicity, education,
or gender.Table 2 Patient experience using MeTree©
N (%)
Ease of use
Computer was easy to use 787/841 (93.6%)
Questions easy to understand 855/885 (96.6%)
Words easy to see 843/867 (97.2%)
Received assistance to complete 311/1184 (26.0%)
Time
I felt rushed 18/854 (2.1%)
Satisfaction
Was a waste of time 12/883 (1.4%)
Made me anxious 32/883 (3.6%)
Preparedness
Had enough information to complete 407/881 (46.2%)
FHH worksheet was helpful 831/859 (96.7%)Satisfaction
The majority of patients were very satisfied with
MeTree©. Only 12/883 (1.0%) felt it was a waste of time
and in multivariate analyses only “Other” ethnicity and
age were significant (OR = 0.14 CI 0.03-0.71 and OR =
0.95 CI 0.90-0.99, respectively).
Preparedness
Most (N = 831/859, 96.7%) felt that the FHH worksheet
(to guide FHH collection) was helpful; no covariates
were significant in multivariate analyses. In addition,
53.9% (N = 638/1184) talked with their relatives about
FHH. Patients reported that by talking to family they
learned: some relatives had diseases they did not know
about (N = 246/638, 38.6%); more relatives had diseases
than they realized (N = 126/638, 19.7%); some relatives’
diseases were more severe than they thought (N = 70/
638, 11.0%); they were mistaken about diseases some rel-
atives had (N = 117/638, 18.3%); and how old relatives
were when they got a disease (N = 186/638, 29.2%). 46%
(N = 407/881) felt they had enough information to
complete MeTree©. Those who wished they had gath-
ered more information tended to: have a larger pedigree
(OR = 0.97, CI 0.95-0.99), have less cancer in their family
(OR = 1.02, CI 1.01-1.04), and were less likely to have
talked with a relative (OR = 1.38, CI 1.01-1.75).
Patient-provider discussion
Of the 1184 study participants, only 370/1184 (31.2%)
answered the survey question regarding discussions with
their provider (Table 3). With the exception of age, these
participants are reflective of the population as a whole,
with no difference in gender, ethnicity, or likelihood of
having received a non-routine recommendation from
MeTree©. Those who were younger were more likely to
answer this question (mean age 57.1 vs. 59.6, p-value =
0.001), though the difference in the ages is not clinically
significant. Discussions related to each CDS condition
are described below.
Breast cancer
Breast cancer risk and management was discussed in
22.7% (N = 48/211) of visits; however, the proportion
was higher in patients receiving a recommendation for
genetic counseling (N = 15/37 (40.5%) vs. N = 33/174
(19.0%), p = 0.004). Routine mammography was discussed in
59% (N= 125/211) of visits and was more common for
those of older age (OR 1.043, CI 1.02-1.07). Breast MRI was
discussed with 4% of women (N= 10/211), of which 5 had a
non-routine breast cancer recommendation (i.e. breast MRI,
chemoprevention, or genetic counseling referral). Those
with routine recommendations for breast cancer risk
were less likely to have this discussion (OR = 0.33, CI
0.09-1.19) than those with non-routine recommendations.
Table 3 Discussions at patient-provider visits
All participants All non-routine
recommendations
Disease-specific non-routine
recommendations
Breast Cancer∞
Risk of breast cancer 48 (22.8%) 29 (23.2%) 18 (32.7%)
Mammography 125 (59.2%) 68 (54.4%) 33 (60.0%)
Breast MRI 10 (4.7%) 8 (6.4%) 5 (9.1%)
Tamoxifen 6 (2.8%) 5 (4%) 4 (7.3%)
Ovarian Cancer∞ 19 (9.0%) 13 (10.4%) 6 (50%)
Colon cancer*
Risk of colon cancer 113 (30.5%) 50 (29.2%) 39 (34.8%)
Screening for colon cancer 260 (70.3%) 118 (69.0%) 83 (74.1%)
Thrombosis* 35 (9.5%) 18 (10.5%) 10 (41.7%)
Seeing a specialist* 82 (22.2%) 62 (36.3%) n/a
Lifestyle choices* 192 (51.9%) 83 (48.5%) n/a
∞Total N = 211 for all participants; 125 for all non-routine recommendations; 55 for breast cancer-specific non-routine recommendations; 12 for ovarian cancer-
specific non-routine recommendations.
*Total N = 370 for all participants; 171 for all non-routine recommendations; 112 for colon cancer-specific non-routine recommendations; 24 for thrombosis-
specific non-routine recommendations.
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visits and was more common among those with a non-
routine breast cancer recommendation (N = 2/20 (10%)
vs. N = 4/191 (2.1%), p = 0.02).
Ovarian cancer
Ovarian cancer was discussed in 19/211 (9%) visits with
female patients. Discussions of ovarian cancer were less
likely if patients had a routine recommendation rather
than non-routine recommendations (i.e. discussion of
ovarian cancer screening or genetic counseling referral)
(OR = 0.07, CI 0.02-0.25).
Colon cancer
Colon cancer risk was discussed in 30.5% (N= 113/370) of
visits, 39 (34.8%) of which were with those who had received
non-routine colon cancer recommendations (i.e. start colon-
oscopy before age 50, start before age 50 and perform more
frequently than every 10 years, or genetic counseling refer-
ral). Discussions were more frequent with males (N= 63/
159 (39.6%) men vs. N = 50/211 (23.7%) women, p = 0.001)
and those with a genetic counseling recommendation
(N = 21 (43.8%) vs. N = 92 (28.8%), p = 0.03). General
discussions regarding colon cancer screening occurred in
the majority of visits (N = 260/370, 70.3%) and were statis-
tically independent of MeTree©’s recommendation.
Thrombosis
Thrombosis risk was discussed in 35/370 (9.5%) visits.
Those with routine recommendations were less likely to
have this discussion (OR = 0.11, CI 0.04-0.27) than those
with non-routine recommendations (i.e. thrombosis gen-
etic testing or genetic counseling referral).Seeing a specialist
Seeing a specialist was discussed in 82/370 (22.2%) visits,
and was most likely in those who had any non-routine
MeTree© recommendation (OR = 5.82, CI 3.21-10.54).
Lifestyle choices
A discussion regarding lifestyle choices occurred during
192/370 (51.9%) visits, regardless of the MeTree© recom-
mendation. Older patients (OR = 0.95, CI 0.93-0.97) and
women (OR = 0.55, CI 0.35-0.86) were less likely to have
such a discussion.
Impressions of MeTree© at 3 months
At 3 months (N = 454, 38.3%) follow-up, patients still had
a strongly positive view of their experience, feeling that it
was helpful to them and their doctor, made them more
aware of their personal risk and family health risk, and
changed how they think about their health (Table 4). In
addition, they would “recommend MeTree© to others”. In
multivariate models positive impressions were not associ-
ated with demographic factors or whether patients re-
ceived a non-routine recommendation from MeTree©.
Regarding what they “wished they knew before using
MeTree©, 55/214 (25.7%) wished they had a greater
knowledge of their FHH. Only 10 had questions regarding
MeTree©’s CDS recommendations or their provider
discussion.
Providers: concerns and experience
There were 14 providers at the intervention sites, 9 phy-
sicians and one nurse practitioner at one and 4 physi-
cians at the other. Demographics are age range 29–65
and 50% female. During pre-implementation interviews,
Table 4 Patients’ perceived benefits of using MeTree©
3 months
N (%)
Respondents 454
Risk awareness
More aware of my risk 389 (85.1%)
More aware of family health risk 415 (89.4%)
Changed how I think about my health 393 (85.8%)
Usefulness
MeTree© was helpful 403 (89.6%)
My pedigree was helpful to me 415 (91.6%)
My pedigree was helpful to my doctor 398 (91.7%)
I would recommend MeTree© to others 421 (92.7%)
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fit of MeTree© and concern that it would impact work-
flow. In particular they reported that: 1) they felt they
were already collecting high quality FHHs; 2) integration
of MeTree© would not lead to clinically important
changes in their patients’ health care plans; 3) patients
would redirect discussions during the appointment to-
wards MeTree© recommendations and away from the
providers’ high priority topics; and 4) MeTree© would
negatively impact work flow either when addressing
questions or implementing recommendations.
On the 3 month post-integration survey providers
were overwhelmingly supportive of MeTree©. In particu-
lar, they felt MeTree©: raised awareness about the im-
portance of FHH and risk stratification, improved the
way they practiced medicine, and made their daily rou-
tine easier; and they reported actively recommending
MeTree© to their peers (Table 5). In addition, MeTree©
made them more aware of the importance of genetic
counselors and genetic counseling (81% wanted to estab-
lish relationships with genetic counselors).Table 5 Provider experience with MeTree© integrated
into practice
Survey question N = 14 (%)
FHH more important now 9 (64%)
Improved practice 12 (86%)
Made practice easier 11 (79%)
Affected workflow 0%
Report was helpful 13 (93%)
Tabular pedigree was helpful 11 (79%)
Disagreed with the report* 0%
Recommend to peers 13 (93%)
*1 provider disagreed with 1 report (out of 1,184).Discussion and conclusions
Using an implementation study process to integrate the
GMM resulted in tremendous support from patients and
providers. This was remarkable considering physicians
had a number of very strong and potentially valid con-
cerns about a negative impact on workflow and the possi-
bility of “hijacking” patient-provider discussions. Further,
physicians often felt they were already adequately captur-
ing FHH and its implications for disease risk in their pa-
tients’ preventive care plans. Implementation of MeTree©
using ongoing feedback and adaptation proved that the
model could be successfully adopted within primary care,
even among busy real world clinical practices. In fact these
practices, as opposed to many clinical trial sites, were not
early adopters who were strongly motivated to see the
intervention succeed; instead they were chosen by the
health system’s administration based upon their size and
diversity. Clinic practices were compensated for participat-
ing, but had no pre-existing interest regarding the out-
comes of the study.
While other electronic FHH and CDS tools exist, to
our knowledge this is the first trial exploring direct inte-
gration of a FHH tool into real world primary care prac-
tices and the first to show that known barriers in the
clinic can be successfully overcome [33-39]. The finding
that patients talked with their family members, acquired
new knowledge about their FHH, and changed their per-
ception of risk, awareness, and attitude towards health
supports the idea that by educating patients on the im-
portance of collecting their FHH and its impact, the
model has the potential to empower patients to take
more responsibility for their care and can improve the
dynamic of the patient-provider relationship. A similar
improvement in risk perception and awareness has also
been seen in other family history studies [33]. In addition,
by providing risk stratification and actionable CDS in
areas that require complex calculations and decision mak-
ing with which most PCPs are not comfortable [9,10],
MeTree©, was able to provide a valuable and time saving
resource.
We examined the patient experience taking important
demographic factors into account, in particular recruit-
ment and satisfaction among minorities and underedu-
cated. There were no significant differences in patient
satisfaction in these groups. In most analyses of patient
experience, age showed a small but statistically signifi-
cant difference in needing more time or assistance. Re-
cruitment and satisfaction among minorities and the
under-educated was the same as the underlying popula-
tion, and though age was statistically significant, the ef-
fect sizes were not clinically significant. Survey results
suggest that the positive patient experience could be at-
tributable to the extensive education available at each
step in the model: collecting FHH, entering FHH into
Wu et al. BMC Family Practice 2013, 14:111 Page 7 of 8
http://www.biomedcentral.com/1471-2296/14/111MeTree©, and risk assessment actions. Nevertheless we
can still improve aspects around collecting FHH and
talking with relatives, especially since those patients who
did talk with relatives were significantly more likely to
feel prepared. Focusing upon expanding tools to further
improve communication among family members could
have a significantly positive impact on the quality of
FHH provided by patients.
MeTree© may improve provider discussions on decision-
making, as shown by the appropriate increase in discus-
sions for patients at higher risk, though some MeTree©
recommendations were not extensively discussed, particu-
larly those related to tamoxifen, ovarian cancer, and throm-
bosis. Several possible explanations exist: failure of patients
to recognize the survey item representing their discussions,
providers not addressing the topic because they were un-
comfortable with it, or providers’ assessment that the rec-
ommendation was inaccurate or inappropriate. The latter
seems unlikely, since few providers disagreed with report
recommendations. One caveat is that those who answered
the patient-provider discussion questions on the survey
were only a subset of the study population, 31%; however,
they were statistically similar to the underlying population
with the exception of age, which at a difference of 2 years
is clinically negligible. The low response rate may have
been due to the fact that there was no option to record that
none of the topics were discussed, which may have been
the case for some patients, and that it was the only ques-
tion located on the reverse side of the survey making it
easy to miss. Another limitation is that the reliability of pa-
tient self-report of discussions with their provider is un-
known. Further research will be necessary to understand
the disparity between recommendations and discussions
during face-to-face time between patients and providers.
An important study limitation is that implementation
study designs allow adaptation to promote GMM
optimization for the current setting, thus there is no as-
surance of generalizability. Further study across a diver-
sity of settings is necessary to better evaluate this. In
addition, several aspects of the GMM are still under
evaluation. In particular we are assessing the accuracy
and quality of the FHH provided as described in sev-
eral previous studies [8,12,13,40-43], the impact of
education on FHH collection and quality, the impact
of CDS on provider care plans and on patients’ pri-
mary prevention and lifestyle behaviors, and its cost-
effectiveness. While study enrollment may seem low,
72% (N = 4,277) of those contacted agreed to partici-
pate. The greatest barrier was only being able to re-
cruit one individual per clinic per one hour time slot
due to kiosk access.
Further study will offer an opportunity to obtain real
world outcomes data on the potential impact of
MeTree© implementation on provider practice andpatient behavior, both in terms of utilization of screening
and genetic counseling and on lifestyle behavior of pa-
tients. Our model lays the groundwork for engaging
community based practices in genomic research by out-
lining a model through which risk assessment and
follow-up counseling and medical management occurs
as a basis for implementing and evaluating a health ser-
vices framework.
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